RIGEL PHARMACEUTICALS INC
S-1, EX-27.1, 2000-09-15
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: RIGEL PHARMACEUTICALS INC, S-1, EX-23.1, 2000-09-15
Next: INVU INC, NT 10-Q, 2000-09-15



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
FINANCIAL STATEMENTS FOR THE SIX MONTH PERIODS ENDED JUNE 30, 1999 AND 2000 AND
IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>                     <C>
<PERIOD-TYPE>                   YEAR                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999             DEC-31-2000
<PERIOD-START>                             JAN-01-1999             JAN-01-2000
<PERIOD-END>                               JUN-30-1999             JUN-30-2000
<CASH>                                           8,574                  15,694
<SECURITIES>                                         0                       0
<RECEIVABLES>                                    1,150                     317
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                 9,999                  16,515
<PP&E>                                          10,813                  13,167
<DEPRECIATION>                                 (2,281)                 (4,397)
<TOTAL-ASSETS>                                  18,675                  25,516
<CURRENT-LIABILITIES>                            7,988                   7,935
<BONDS>                                              0                       0
                                0                       0
                                         22                      25
<COMMON>                                             3                       4
<OTHER-SE>                                       6,176                  11,229
<TOTAL-LIABILITY-AND-EQUITY>                    18,675                  11,258
<SALES>                                              0                       0
<TOTAL-REVENUES>                                 3,069                   6,797
<CGS>                                                0                       0
<TOTAL-COSTS>                                    8,538                  17,630
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                                 154                     455
<INCOME-PRETAX>                                      0                       0
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                                  0                       0
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                   (5,457)                (10,801)
<EPS-BASIC>                                     (2.02)                  (2.60)
<EPS-DILUTED>                                   (2.02)                  (2.60)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission